MARKET

CEMI

CEMI

Chembio Diagnostics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6400
-0.0174
-2.65%
Closed 18:01 05/20 EDT
OPEN
0.6797
PREV CLOSE
0.6574
HIGH
0.6900
LOW
0.6100
VOLUME
174.11K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
0.4152
MARKET CAP
19.34M
P/E (TTM)
-0.4436
1D
5D
1M
3M
1Y
5Y
Chembio's inks contract for HIV test to be made by Reszon Diagnostics at Malaysia facility
Chembio Diagnostics (NASDAQ:CEMI) signed an agreement under which Reszon Diagnostics International will manufacture its HIV 1/2 STAT-PAK Assay products in the Chembio Diagnostics Malaysia facility, which had previously suspended operations in May
Seekingalpha · 5d ago
BRIEF-Chembio Diagnostics Announces Agreement For Reszon Diagnostics To Manufacture Chembio's HIV 1/2 STAT-PAK Assay At Co's Malaysia Facility
reuters.com · 5d ago
Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility
HAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has entered into a manufacturing agreement with Reszon Diagn...
GlobeNewswire · 5d ago
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 05/16 09:23
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
Chembio Diagnostics GAAP EPS of -$0.29 misses by $0.08, revenue of $18.82M beats by $7.02M
Chembio Diagnostics press release (NASDAQ:CEMI): Q1 GAAP EPS of -$0.29 misses by $0.08. Revenue of $18.82M (+115.8% Y/Y) beats by $7.02M.
Seekingalpha · 05/05 20:19
-- Earnings Flash (CEMI) CHEMBIO DIAGNOSTICS Posts Q1 Loss $-0.29, vs. Street Est of $-0.21
MT Newswires · 05/05 17:12
More
No Data
Learn about the latest financial forecast of CEMI. Analyze the recent business situations of Chembio Diagnostics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CEMI stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
High8.00
Average8.00
Low8.00
Current 0.6400
EPS
Actual
Estimate
-0.38-0.28-0.19-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 79
Institutional Holdings: 4.65M
% Owned: 15.39%
Shares Outstanding: 30.22M
TypeInstitutionsShares
Increased
5
11.97K
New
3
142.03K
Decreased
16
1.05M
Sold Out
11
268.90K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.90%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Katherine Davis
President/Chief Executive Officer/Director
Richard Eberly
Chief Financial Officer
Lawrence Steenvoorden
Chief Operating Officer/Executive Vice President
Paul Angelico
Executive Vice President/Chief Technology Officer/Chief Scientific Officer
Javan Esfandiari
Senior Vice President
Charles Caso
Independent Director
David Acheson
Independent Director
David Bespalko
Independent Director
John Potthoff
No Data
No Data
About CEMI
Chembio Diagnostics, Inc. develops, manufactures and commercializes point-of-care tests for the detection and diagnosis of infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Its DPP technology offers range of market applications beyond infectious disease. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in approximately 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases, cardiac markers, cholesterol and lipids, pregnancy and fertility, and drugs of abuse. It targets rapid diagnostic test solutions for infectious diseases, including respiratory diseases, sexually transmitted diseases, gastroenterology and insect-vector diseases. The Company sells its products under the DPP, STAT PAK, SURE CHECK and STAT-VIEW trademarks.

Webull offers kinds of Chembio Diagnostics Inc stock information, including NASDAQ:CEMI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CEMI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CEMI stock methods without spending real money on the virtual paper trading platform.